Viewing nowCombinationOlotenshon Tablet 5/40 mg (Amlodipine Besilate, Olmesartan Medoxomil)
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Pharmaceutical Co., Ltd.

MFDS item code 201505940 · Approved 2015.08.25 · Insurance code 642802780
Treatment of essential hypertension not controlled with monotherapy
This medication is used to adequately lower and control blood pressure in patients with essential hypertension who find it difficult to achieve blood pressure control with monotherapy using either Amlodipine or Olmesartan Medoxomil alone.
Administer 1 tablet once daily with water, with or without food. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy with either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and administration of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced intravascular volume: In patients who may have reduced intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ○ Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and coexisting diseases. In elderly patients, blood pressure should be monitored closely and more frequently.
○ Pediatric patients: The safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication may cause serious harm to the fetus and newborn if taken during the second or third trimester of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Patients with hypersensitivity to the active ingredients of this medication, pregnant and breastfeeding women, patients with severe liver impairment, severe aortic stenosis, bile duct obstruction, renal dialysis, shock, and specific diabetic patients and renal impairment patients should not be given this medication. In patients with hypotension caused by fluid or salt depletion, hypotensive symptoms may occur, so their condition should be closely monitored during the initial administration, and appropriate measures should be taken if hypotension occurs. Acute hypotension may occur after taking this medication due to vasodilation, so particular caution is required for patients with severe aortic stenosis. Patients with severe obstructive coronary artery disease should exercise caution as the risk of angina or myocardial infarction may increase when taking this medication. Use this medication carefully in patients with congestive heart failure, and monitor carefully for changes in renal function in patients with renal impairment. Patients with liver dysfunction should be cautious as metabolism and excretion of this medication may be delayed. While taking this medication, side effects such as dizziness, headache, hypotension, orthostatic hypotension, edema, dyspepsia, etc., may arise, so if there are any unusual symptoms, immediate consultation with healthcare professionals is recommended. This medication may interact with other drugs, so if there are other medications being taken, it is essential to inform healthcare professionals, especially avoiding concurrent use with grapefruit juice. This medication should not be taken during pregnancy, and breastfeeding women are advised to discontinue breastfeeding or the medication since it may pass into breast milk. Safety and effectiveness have not been established for pediatric patients under 18 years of age, so it is not recommended for use in this population. For the elderly, starting at a lower dose is recommended considering renal and liver function decline. In case of overdose, hypotension and impaired heart function may occur, so immediate medical attention is required for appropriate treatment. This medication should be stored out of the reach of children and protected from moisture, heat, and direct sunlight.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. Additionally, it is advisable to store the medication at a normal room temperature between 1 and 30 degrees Celsius, not in excessively hot or cold places.
Pale yellow, round, film-coated tablets
28 tablets (14 tablets/PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.